Biologics by McKesson

02/16/2026

Patients are at the heart of everything we do at Biologics. We know that every action, no matter how small, can have a big impact on someone's life. Our goal is to be a source of information and support for each patient we work with.

Brennan Betterly, Sr. Program Analyst, Strategic Accounts, put it best:

"Working at Biologics reminds me every day that even small actions can change the course of someone’s hardest moments. I’m grateful to be part of a team that helps patients feel supported, informed, and hopeful."

Patients come to us during difficult times, and our team is here to help them feel seen and make sure their questions get answered. As Brennan says, "What we do here is meaningful to me because it helps patients feel seen, supported, and cared for during vulnerable moments. That’s the heart of Biologics to me."

Thanks for sharing your "why," Brennan! We're glad to have you on the team.

Join us: https://biologics.mckesson.com/careers/

02/13/2026

When a child is diagnosed with cancer, every family deserves hope – and access to the care that can help. Around the world, survival rates can be very different because families don’t always have the same resources or access to treatment. These differences show how important it is to improve care for every child, no matter where they live.

International Childhood Cancer Day is this Sunday (February 15th). Every year, this day gives us a chance to show support for children with cancer and their families. That includes doing everything we can to make sure they get the support they need.

At Biologics, we want every child to be able to get care. That's why we're proud to support the children and their families who are bravely fighting cancer every day. Together, we can keep working toward better treatments for everyone.

02/12/2026

Cell and gene therapies (CGTs) are reshaping what’s possible in patient care, but getting access to them can still be tough.

In the article below, Biologics president Ela Lourido and Joe DePinto of InspiroGene by McKesson look at how specialized hubs can lead to better outcomes for CGTs.

As the hub provider for InspiroGene, we know that hubs for CGT can’t be “one-size-fits-all.” They must be built with each individual patient and their needs in mind. We're proud to use our experience with CGTs to help patients get the care they need.

Learn more below.

Cell and gene therapy patients face a treatment journey unlike any other. Traditional hubs were not built for this level of clinical, logistical, and financial complexity. Joe DePinto and Ela Lourido share why purpose-built hubs, supported by dedicated case management and integrated technology,...

02/11/2026

Biologics is proud to be partners with rare disease advocacy groups that help spread awareness and hope. Their work is key to moving the research forward and making new treatments available to those who need them.

As we get closer to Rare Disease Day on February 28th, we want to shine the spotlight on some of our partners and the great work they're doing.

🔬 Friedreich's Ataxia Research Alliance (FARA): This group supports research into a cure for FA. FARA offers grants and helps build community for those living with the disease. Their work has led to more targeted approaches to treatment.

💻 TGCT Support: This group has created a central hub of information that includes the latest research on TGCT. Their partnerships also help connect the patient community.

🤝 National Organization for Rare Disorders, Inc. (NORD): This group provides support for those living with rare diseases. It also encourages research and policy. NORD has over 350 member groups focused on finding cures.

Thank you to our partners for putting patients first! We're proud to stand with you to get rare disease patients the care and support they need.

02/09/2026

Did you know that many cancers may be prevented with healthy habits and regular screenings?

Cancer can’t always be prevented, but you can take steps to lower your risk. Healthy habits and regular screenings are some of the most effective tools we have.

That's why Biologics focuses on more than just cancer treatment. We’re committed to supporting better health for all.

February is Cancer Prevention Month, and we’re joining our partners in sharing information that can help prevent cancer. Here are five ways to lower cancer risk: https://www.cancer.org/cancer/risk-prevention.html

02/06/2026

When it comes to helping patients, Biologics goes above and beyond. Our goal is to make sure patients get their medications and the support they need, no matter what.

During our holiday party, Ben Matherne, VP of Business Insights & Special Projects, shared several stories that highlight the way we rise to the challenge of meeting urgent patient needs.

Watch the full video to see how our team is putting patients first.

02/04/2026

Behind every cancer diagnosis, there is a real person and their story.

Today, February 4th, is World Cancer Day. This is a time to raise awareness of cancer research and prevention. It's also a time to reflect on how we can honor the experiences of those living with these diseases.

This year's theme is "United by Unique." It reminds us to focus on the patients, families, and communities affected by cancer and why their stories matter.

At Biologics, we're proud to work with the brave patients we see every day and make sure they get the support they need.

02/02/2026

Living with a rare disease can feel isolating. The road to diagnosis is often long and uncertain, and for most conditions, treatment doesn’t yet exist. That’s why raising awareness is so important. Each patient has an important story to tell, and with Rare Disease Day coming up on Feb. 28th, we have a great opportunity to do so.

Biologics is dedicated to using our decades of experience to help patients navigate the complex world of rare disease. We know there are a lot of details to keep track of, and our team is here to help. We're proud to stand by those who are bravely facing these diseases and inspiring us all.

01/30/2026

Did you know that thyroid cancer is the most common kind of endocrine cancer? While it often develops silently, it's usually treatable if found early. Genetic factors and radiation may increase the risk of thyroid cancer.

Thyroid cancer starts in the thyroid—a small, butterfly-shaped gland in the neck. This gland produces hormones that control metabolism, heart rate, and body temperature. When thyroid cells mutate, they grow uncontrollably and form tumors.

— About 44,000 new cases of thyroid cancer are expected in the U.S. in 2025, making up 2.2% of all new cancer cases.

— Women are three times more likely to develop thyroid cancer than men.

— There may not be any symptoms early on. Later signs may include a neck lump, hoarseness, difficulty swallowing, or neck pain.

Better awareness ensures that patients speak with their doctors earlier if they notice any symptoms. It also supports ongoing research for better treatments. All of this can help save lives.

At Biologics, we stand with patients, caregivers, and healthcare providers who are helping to make progress in the fight against thyroid cancer.

🔗 Learn more: https://www.cancer.org/cancer/types/thyroid-cancer.html

01/28/2026

The work we do at Biologics is about more than just making sure patients get their medications. It's also about delivering high-touch support to the people who need it. In other words, it's about offering help throughout the treatment journey.

"I will always remember the first patient I called to schedule a refill," says Mary Falco Magri, Client Management Specialist. "That one phone call creates a huge impact to the patient’s life, knowing they are receiving their therapy on time."

Thank you for living our values and being there for our patients, Mary! We're glad to have you on the team.

Join us: https://biologics.mckesson.com/careers/

01/26/2026

Today, we’d like to shine a light on Molybdenum Cofactor Deficiency Type A (MoCD-A). This rare genetic disorder affects newborns, and it may go undetected until symptoms start to progress. This can happen very quickly.

MoCD-A is caused by mutations in the MOCS1 gene that make it harder for the body to remove harmful substances. Toxins build up, which can lead to severe brain damage. Babies may have trouble sitting up on their own or learning to speak.

Did you know?

— About 1 in 342,000 to 411,000 babies worldwide are known to have been born with MoCD-A. However, the real number of cases is probably larger since not every child with it gets a diagnosis.

— Babies with MoCD-A look healthy at birth. But within days, they start to develop feeding problems and seizures.

— MoCD-A moves fast and can cause major developmental delays.

Early diagnosis is critical. That means looking out for symptoms like seizures, poor feeding, and strong startle responses. This can be tough because these symptoms are common in other conditions, too. That's why awareness is so important: It helps families, drives research, and leads to life-saving treatment.

At Biologics, we're proud to stand with all of those who are bringing hope to the fight against MoCD-A and other rare diseases.

🔗 Learn more: https://rarediseases.org/rare-diseases/molybdenum-cofactor-deficiency-mocd/

01/23/2026

At the beginning of the year, many insurance plans reset. For providers and patients, this can be a busy time with lots of details to stay on top of. For providers, that often means reverifying coverage to keep care moving without delays.

Biologics helps by reverifying coverage to prevent interruptions in care. We're grateful for our knowledgeable, hardworking staff, who go out of their way to make sure patients get the support they need. Thank you for living our mission of putting patients first! We couldn't do this without you.